Skip to content
Open access

Six-Month Surgical Outcomes of Ahmed ClearPath™ ST250 Implantation in Seven Eyes With Refractory Glaucoma: A Case Series

Sep 2026 · Cureus · Vol 18 · 0 citations · 11 references
Medicine

TL;DR

It is suggested that Ahmed ClearPath™ ST250 might be a useful surgical option for the management of refractory glaucoma and five of seven patients were glaucoma medication-free after surgery at six months.

Abstract

Purpose: The purpose of this study is to evaluate the short-term clinical outcomes of Ahmed ClearPath™ small tube (ST) 250 implantation in patients with refractory glaucoma. Methods: This retrospective study included seven consecutive patients who underwent Ahmed ClearPath™ ST250 implantation at Nagoya University Hospital between December 2025 and April 2026. The primary outcome measure was intraocular pressure (IOP) at six months. Results: The mean age at surgery was 68.7 ± 17.7 years, and the median age was 74 years (range: 42-87 years). Four eyes had primary open-angle glaucoma, and one eye each had glaucoma secondary to retinal detachment surgery, uveitis, and Descemet stripping automated endothelial keratoplasty. Preoperative average IOP was 35.0 ± 6.6 mmHg, and median IOP was 32.0 mmHg (range: 28.0-45.0 mmHg). After Ahmed ClearPathTM ST surgery, IOP decreased to 15.7 ± 9.9 mmHg in one day, median IOP: 12.0 mmHg (range: 5.0-30.0 mmHg), 17.1 ± 12.1 mmHg, median IOP: 11.0 mmHg (range, 6.0-40.0 mmHg) in one week, 13.2 ± 8.2 mmHg, median IOP: 14.0 mmHg (range, 3.0-26.0 mmHg) in two weeks, 10.8 ± 4.1 mmHg, median IOP: 10.5 mmHg (range, 6.0-18.0 mmHg) in one month, 16.2 ± 8.0 mmHg, median IOP: 16.5 mmHg (range: 6.0-28.0 mmHg) in three months, and 11.0 ± 2.7 mmHg, median IOP: 12.0 mmHg (range: 7.0-14.0 mmHg) in six months. Stent removal was performed in five eyes on postoperative days 7, 13, 14, 90, and 90, whereas the stent remained in two eyes throughout the follow-up period. Five of seven patients were glaucoma medication-free after surgery at six months. No shallow or flat anterior chamber, choroidal detachment, suprachoroidal hemorrhage, hypotony maculopathy, or conjunctival leakage were observed. Numerical hypotony, defined as an IOP of <6 mmHg, was observed in two cases but resolved spontaneously without any specific treatment. Conclusions: Ahmed ClearPath ST250 implantation achieved IOP reduction. These findings suggest that Ahmed ClearPath™ ST250 might be a useful surgical option for the management of refractory glaucoma.

Read PDF

Similar papers

Open access Oct 2026

Long-term Evaluation of the Efficacy and Safety of the EX-PRESS® Glaucoma Drainage Device in the Treatment of Primary Open-Angle Glaucoma: A Five-Year.

AIM To evaluate the long-term efficacy and safety of the EX-PRESS glaucoma drainage device implantation in patients with primary open-angle glaucoma over a five-year follow-up period. MATERIALS AND METHODS The retrospective analysis included 77 eyes of 58 patients (28 women, 30 men) who underwent EX-PRESS glaucoma dr...

Veronika Fialová, M. Váša, P. Rozsíval et al. · 0 citations
Review Open access Sep 2026

Pilot Outcomes of Cataract Extraction with Modified Ahmed ClearPath 250 Retrobulbar/Intraconal Glaucoma Drainage Device Implantation with Inferior Sclerotomy in Patients with Advanced Glaucoma: A 1-year Retrospective Study

At 1 year, the modified retrobulbar/intraconal placement of the Ahmed ClearPath 250 GDD achieves substantial intraocular pressure lowering, reduces the need for topical medications, and supports the short-term feasibility of this promising procedure.

Louis K. Aghanwa, Laila Abouhasswa Od, D. Laroche · 0 citations
Oct 2026

Scleral-Tunneled, Graft-Free Glaucoma Drainage Device Implantation in Children: Outcomes from a US Tertiary Center.

ST-GDD resulted in sustained IOP reduction, decreased medication burden, and zero tube exposures, the first US report of ST-GDD outcomes in children, and long-term prospective comparisons with conventional patch-graft techniques are needed.

Musse Hussein, Zi-Yan Jiang, Raymond G. Areaux · 0 citations
Open access Sep 2026

Clinical outcomes of the PAUL® glaucoma implant for secondary glaucoma.

PURPOSE Secondary glaucoma encompasses a broad spectrum of disease entities arising from diverse ocular pathologies and is often refractory to conventional treatment. Glaucoma drainage devices (GDDs) have therefore become an important surgical option. This study evaluates the efficacy and safety of the PAUL® Glaucoma I...

C. Deubel, B. Aretz, Wolfgang Walz et al. · 0 citations
Open access Oct 2026

A-stream Shunt Implantation for Secondary Glaucoma after Penetrating Keratoplasty: A Case Series.

Purpose To evaluate the clinical outcomes of A-stream glaucoma shunt implantation for medically refractory secondary glaucoma after penetrating keratoplasty (PKP). Methods This retrospective interventional case series included four eyes of four patients with uncontrolled secondary glaucoma following PKP who underwent...

Seong Bin Heo, Min Gu Huh · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.